| Nanoparticles functionalised with an anti-platelet human antibody for in vivo detection of atherosclerotic plaque by magnetic resonance imaging MJ Jacobin-Valat, J Laroche-Traineau, M Larivière, S Mornet, S Sanchez, ... Nanomedicine: Nanotechnology, Biology and Medicine 11 (4), 927-937, 2015 | 49 | 2015 |
| Multimodal molecular imaging of atherosclerosis: Nanoparticles functionalized with scFv fragments of an anti-αIIbβ3 antibody M Larivière, CS Lorenzato, L Adumeau, S Bonnet, A Hémadou, ... Nanomedicine: Nanotechnology, Biology and Medicine 22, 102082, 2019 | 21 | 2019 |
| Iron oxide core oil-in-water nanoemulsion as tracer for atherosclerosis MPI and MRI imaging G Prévot, T Kauss, C Lorenzato, A Gaubert, M Larivière, J Baillet, ... International Journal of Pharmaceutics 532 (2), 669-676, 2017 | 21 | 2017 |
| A Recombinant Human Anti-Platelet scFv Antibody Produced in Pichia pastoris for Atheroma Targeting A Vallet-Courbin, M Larivière, A Hocquellet, A Hemadou, SN Parimala, ... PLoS One 12 (1), e0170305, 2017 | 17 | 2017 |
| Nanomedicine in thrombosis and hemostasis: the future of nanotechnology in thrombosis and hemostasis research and clinical applications CE Hagemeyer, T Lisman, HC Kwaan Seminars in thrombosis and hemostasis 46 (05), 521-523, 2020 | 4 | 2020 |
| Recent advances in the molecular imaging of atherosclerosis M Lariviere, S Bonnet, C Lorenzato, J Laroche-Traineau, F Ottones, ... Seminars in Thrombosis and Hemostasis 46 (05), 563-586, 2020 | 3 | 2020 |
| Data on atherosclerosis specific antibody conjugation to nanoemulsions G Prévot, M Duonor-Cérutti, M Larivière, J Laroche-Traineau, ... Data in brief 15, 824-827, 2017 | 3 | 2017 |
| Le Club anticorps de la Societé française d’immunologie-Structurer les atouts de la recherche française M Larivière, R Monteiro médecine/sciences 35 (12), 1206-1207, 2019 | 1 | 2019 |
| Players from the program" Investments for the Future": MAbImprove MabEx M Larivière, A Pèlegrin, P Martineau, H Watier Medecine Sciences: M/S 35 (12), 1204-1205, 2019 | | 2019 |
| Actualités des anticorps monoclonaux dans les maladies monogéniques aujourd’hui A Bauvois, M Larivière, H Watier, F Maillot médecine/sciences 35 (12), 1026-1028, 2019 | | 2019 |
| The Antibody Club of the French Society of Immunology: structuring the assets of French research M Larivière, R Monteiro Medecine Sciences: M/S 35 (12), 1206-1207, 2019 | | 2019 |
| Monoclonal antibodies for monogenic diseases: a 2019 update A Bauvois, M Larivière, H Watier, F Maillot Medecine Sciences: M/S 35 (12), 1026-1028, 2019 | | 2019 |
| Acteurs issus du programme d’investissements d’Avenir (PIA)-le LabEx MAbImprove M Larivière, A Pèlegrin, P Martineau, H Watier médecine/sciences 35 (12), 1204-1205, 2019 | | 2019 |
| Chapitre 3: De la biologie de synthèse aux biomédicaments A Bradier, J Leclerc, M Larivière, G Brachet, H Watier Chimie et biologie de synthèse, 57-66, 2019 | | 2019 |
| Nanoparticles functionalized with human antibodies for multimodal molecular imaging of atherosclerosis M Larivière Université de Bordeaux, 2016 | | 2016 |
| Les anticorps monoclonaux dans le domaine de la santé M Larivière | | 2013 |
